Onsite QTc interval screening for patients in methadone maintenance treatment

Journal of Addictive Diseases

Volumn 29, Issue 1, 2010, Pages 15-22

  Fareed, Ayman ^a,b   Vayalapalli, Sreedevi ^b   Byrd Sellers, Johnita ^b   Casarella, Jennifer ^a   Drexler, Karen ^a   Amar, Richard ^a   Smith Cox, Jocelyn ^b   Lutchman, Tamara Shaw ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Methadone maintenance; Onsite; QTc interval; Screening

Indexed keywords

ANTIDEPRESSANT AGENT; COCAINE; METHADONE; NEUROLEPTIC AGENT; OPIATE; NARCOTIC AGENT;

ACCURACY; AFRICAN AMERICAN; CARDIOVASCULAR RISK; DEMOGRAPHY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HUMAN; MAINTENANCE THERAPY; MEDICAL RECORD; OUTCOME ASSESSMENT; QT INTERVAL; QT PROLONGATION; REVIEW; SMOKING; TREATMENT DURATION; TREATMENT PLANNING; AGED; CHEMICALLY INDUCED; DOSE RESPONSE; ELECTROCARDIOGRAPHY; FEASIBILITY STUDY; FEMALE; HEART MUSCLE CONDUCTION SYSTEM; LONG QT SYNDROME; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEASIBILITY STUDIES; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; MALE; MEDICAL RECORDS; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77951243730     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880903436044     Document Type: Review

References (40)

1. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer HL, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290-1297
2. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88:34-39 (Pubitemid 28109638)
3. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 2000; 57:395-404. (Pubitemid 30202331)
4. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965; 193: 80-84
5. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966; 66: 2011-2017
6. Marsch, LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior, and criminality: a meta-analysis. Addiction 1998; 93:515-532
7. Zanis DA,Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998; 52:257-260
8. Woody GE, Kane V, Lewis K, Thompson R. Premature deaths after discharge from methadone maintenance: a replication. J Addict Med 2007; 1:180-185
9. Routhier DD, Katz KD, Brooks DE. QTc prolongation and Torsades De Pontes associated with methadone therapy. J Emer Med 2007; 32:275-278
10. Krantz M, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137:501-504 (Pubitemid 35024621)
11. Cruciani RA. Methadone: to ECG or not to ECG. . .that is still the question. J Pain Symptom Manage 2008; 36:545-552
12. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovas Dis 2001; 431:1-45.
13. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Internal Med 1995; 122:701-714.
14. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167:2469-2475
15. Latowsky M. Methadone death, dosage, and torsade de pointes: risk-benefit policy implications. J Psychoactive Drugs 2006; 38:513-519 (Pubitemid 46340096)
16. Roden DM. Drug-induced prolongation of the QT interval. N Eng J Med 2004; 350(1):1013-1022
17. Huffman JC, Stern TA. QTc prolongation and the use of antipsychotics: a case discussion. PrimaryCareCompanion J Clin Psychiatry 2003; 5:96.
18. Vieweg WVR. New generation antipsychotic drugs and QTc internval prolongation. Primary Care Companion J Clin Psychiatry 2003; 5(5):205-215
19. Zareba W. Drug induced QT prolongation. Cardiol J 2007; 14:523-533 (Pubitemid 351278615)
20. Peles E, Bodner G, Kreek MJ, Rados V, AdelsonM. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 2007; 102:289-300. (Pubitemid 46096291)
21. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105:499-506. (Pubitemid 37186911)
22. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11:44-49 (Pubitemid 40082210)
23. EhretGB,VoideC,Gex-Fabry M, Chabert J, ShahD, Broers B, Pisuet V, Musset T, Gaspoz JM, Perrier A, Dayer P, Desmeules JA. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280-1287 (Pubitemid 43967579)
24. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007; 93:1051-1055 (Pubitemid 47310981)
25. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Sheu RG, Portenoy RK. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005; 29:385-391 [PMID: 15857742]. (Pubitemid 40602519)
26. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95:915-918 (Pubitemid 40386816)
27. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802-805 (Pubitemid 36629083)
28. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential forQT interval prolongation by non-cardiovascular medicinal products. London: The European Agency for the Evaluation of Medicinal Products, 1997.
29. U.S. Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. Rockville, MD: Center for Drug Evaluation and Research, 2005.
30. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc.AmJ Cardiol 2002; 89:1316-1319
31. http://www.fda.gov/CDER/drug/advisory/methadone. htm (accessed 1/9/09).
32. Dolophine Hydrochloride CII (Methadone Hydrochloride Tablets, USP) 5 mg, 10 mg, Rx Only. Columbus, OH: Roxane Laboratories, 2006. www.fda.gov/cder/ foi/label/2006/006134s028lbl.pdf (accessed November 12, 2008).
33. Product Discontinuation Notice: Orlaam (Levomethadyl Hydrochloride Acetate) Oral Solution, 10 mg/mL, CII. Columbus, OH: Roxane Laboratories, 2003. www.fda.gov/cder/drug/shortages/orlaam.htm (accessed November 12, 2008).
34. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MCP. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387-395
35. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psych Pract 2009; 15:227-234
36. Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts: a Veterans Administration cooperative study. Arch Gen Psychiatry 1976; 33:709-720
37. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23-27 (Pubitemid 23177293)
38. Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000; 36:1-12. (Pubitemid 30466104)
39. Katchman AN, McGroary KA, KilbornMJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN. Influence of opioid agonists on cardiac human ether-a-go-gorelated gene K( ) currents. J Pharmacol Exp Ther 2002; 303:688-694
40. Ferreira S, Crumb WJ Jr, Carlton CG, Clarkson CW. Effects of cocaine and its major metabolites on the HERGencoded potassium channel. J Pharmacol Exp Ther 2001; 299:220-226 (Pubitemid 32905138)